Sugi Predict

Sugi Predict / Compounds / SCHEMBL758787

SCHEMBL758787

SCHEMBL758787

CC(C)(C)OC(=O)N1CCc2ncccc21

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.47
▸ KDM1A O60341 1/20 0.45
▸ MAPT P10636 1/20 0.44
▸ GPR119 Q8TDV5 3/20 0.43
▸ GRM5 P41594 3/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ UCHL1 P09936 2/20 0.41
▸ DTYMK P23919 1/20 0.41
▸ BCHE P06276 1/20 0.40
▸ AKT1 P31749 1/20 0.39
▸ GRM1 Q13255 2/20 0.39
▸ KCNQ2 O43526 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30900485 1.00 POLB (0.47) POLBKDM1AMAPTGPR119GRM5
SCHEMBL27094830 0.92 POLB (0.45) POLBKDM1AMAPTGPR119GRM5
SCHEMBL15467836 0.84 POLB (0.45) POLBKDM1AMAPTGPR119GRM5
SCHEMBL15467898 0.83 POLB (0.44) POLBKDM1AMAPTGPR119GRM5
SCHEMBL15467011 0.80 POLB (0.44) POLBKDM1AMAPTGPR119GRM5
SCHEMBL15632547 0.79 NOTUM (0.56) POLBAKT1
SCHEMBL15467026 0.78 POLB (0.43) POLBKDM1AMAPTGPR119GRM5
Hydrochloric Acid SCHEMBL15648804 0.78 NOTUM (0.54) POLBAKT1
SCHEMBL30462275 0.78 POLB (0.47) POLBMAPTGPR119GRM5HDAC1
SCHEMBL29173113 0.78 KDM1A (0.43) KDM1AMAPTGPR119GRM5HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745134-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-20 — — EP disclosed
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2026-05-07 — — US disclosed
US-12522587-B2 Cancer treatments targeting cancer stem cells REMEDY PLAN, INC. (US) 2026-01-13 — — US disclosed
EP-3703692-B1 NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-07-23 — — EP disclosed
US-12275729-B2 Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2025-04-15 — — US disclosed
WO-2025016323-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-23 — — WO disclosed
CN-115368356-A Bicyclic heterocyclic compounds and their therapeutic use 阿斯特克斯治疗有限公司 2022-11-22 — — CN disclosed
US-20220324842-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2022-10-13 — — US disclosed
CN-109336883-B Bicyclic heterocyclic compounds and their therapeutic use 阿斯特克斯治疗有限公司 2022-06-14 — — CN disclosed
US-20210179607-A1 NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-06-17 — — US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 — — US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 — — US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 — — US disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 — — WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 — — WO disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 — — US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 — — US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 — — US disclosed
EP-1680423-A1 AZABENZODIAZEPINES AS PHOSPHODIESTERASE-4 INHIBITORS Warner-Lambert Company LLC (US) 2006-07-19 — — EP disclosed
WO-2005040168-A1 AZABENZODIAZEPINES AS PHOSPHODIESTERASE-4 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179607-A1 NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU POLB 3003/4885KDM1A 321/4885MAPT 1407/4885
US-20120052130-A1 GPR 119 MODULATORS GPR119, GPR39, GPR65 POLB 4573/4885KDM1A 3691/4885MAPT 4026/4885
US-20100285145-A1 GPR 119 MODULATORS GPR119, GPR65, GPR39 POLB 4496/4885KDM1A 3574/4885MAPT 3590/4885
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, MALT1, BCL6 POLB 2748/4885KDM1A 1337/4885MAPT 4022/4885
US-12275729-B2 Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, INMT POLB 2689/4885KDM1A 411/4885MAPT 1318/4885
US-20220324842-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, CD47, GLI1 POLB 2980/4885KDM1A 394/4885MAPT 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.